GCG and type 2 diabetes mellitus: Furthermore, the advancement of precision medicine approaches, which combine progress in pharmacogenomics with established knowledge of the heterogeneous pathological processes underlying the aetiology of type 2 diabetes, holds the potential to uncover distinct subsets of individuals who are differentially responsive to the beneficial cardiometabolic actions of incretin-based therapies [81].